{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:45:01Z","timestamp":1792028701647,"version":"4.4.0"},"reference-count":95,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T00:00:00Z","timestamp":1637539200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.tranon.2021.101295","type":"journal-article","created":{"date-parts":[[2021,11,26]],"date-time":"2021-11-26T23:30:50Z","timestamp":1637969450000},"page":"101295","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Nephrotoxicity after radionuclide therapies"],"prefix":"10.1016","volume":"15","author":[{"given":"Ashwin Singh","family":"Parihar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sejal","family":"Chopra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tranon.2021.101295_bib0001","first-page":"25","article-title":"Radioiodine I-131 for the therapy of graves\u2019 disease","volume":"16","author":"Mumtaz","year":"2009","journal-title":"Malays. J. Med. Sci."},{"key":"10.1016\/j.tranon.2021.101295_bib0002","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S0140-6736(03)12488-9","article-title":"Thyroid carcinoma","volume":"361","author":"Sherman","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.tranon.2021.101295_bib0003","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1007\/978-3-319-26236-9_26","article-title":"Neuroendocrine tumors: therapy with 131I-MIBG","author":"Carrasquillo","year":"2017","journal-title":"Nucl. Oncol."},{"key":"10.1016\/j.tranon.2021.101295_bib0004","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S1470-2045(05)70206-0","article-title":"Radioisotopes for the palliation of metastatic bone cancer: a systematic review","volume":"6","author":"Finlay","year":"2005","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tranon.2021.101295_bib0005","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1053\/j.semnuclmed.2019.01.003","article-title":"The role of radioembolization in bridging and downstaging hepatocellular carcinoma to curative therapy","volume":"49","author":"Titano","year":"2019","journal-title":"Semin. Nucl. Med."},{"key":"10.1016\/j.tranon.2021.101295_bib0006","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tranon.2021.101295_bib0007","doi-asserted-by":"crossref","first-page":"314","DOI":"10.2967\/jnmt.117.197400","article-title":"Imaging-guided use of combined 177Lu-DOTATATE and capecitabine therapy in metastatic mediastinal paraganglioma","volume":"45","author":"Ashwathanarayana","year":"2017","journal-title":"J. Nucl. Med. Technol."},{"key":"10.1016\/j.tranon.2021.101295_bib0008","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.2967\/jnumed.115.168443","article-title":"177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy","volume":"57","author":"Baum","year":"2016","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.tranon.2021.101295_bib0009","first-page":"67","article-title":"Orbital and brain metastases on 68Ga-PSMA PET\/CT in a patient with prostate carcinoma refractory to 177Lu-PSMA and 225Ac-PSMA therapy","volume":"9","author":"Parihar","year":"2021","journal-title":"Asia Ocean J. Nucl. Med. Biol."},{"key":"10.1016\/j.tranon.2021.101295_bib0010","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/RLU.0000000000002001","article-title":"Unusual Case of Diffuse penile metastasis of prostate cancer on 68Ga PSMA PET\/CT imaging and 177Lu PSMA posttherapy scintigraphy","volume":"43","author":"Vadi","year":"2018","journal-title":"Clin. Nucl. Med."},{"key":"10.1016\/j.tranon.2021.101295_bib0011","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nrc3925","article-title":"Radioimmunotherapy of human tumours","volume":"15","author":"Larson","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.tranon.2021.101295_bib0012","article-title":"Safety and therapeutic value of radiosynoviorthesis with yttrium-90: a Canadian single-centre experience","author":"Zeiadin","year":"2020","journal-title":"Rheumatology"},{"key":"10.1016\/j.tranon.2021.101295_bib0013","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1007\/s00259-020-04859-y","article-title":"Fibroblast activation protein inhibitor (FAPI) PET for diagnostics and advanced targeted radiotherapy in head and neck cancers","volume":"47","author":"Syed","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.tranon.2021.101295_bib0014","doi-asserted-by":"crossref","first-page":"248","DOI":"10.2967\/jnumed.115.167361","article-title":"First-in-human experience of CXCR4-directed endoradiotherapy with 177Lu-and 90Y-labeled pentixather in advanced-stage multiple myeloma with extensive intra-and extramedullary disease","volume":"57","author":"Herrmann","year":"2016","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.tranon.2021.101295_bib0015","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1089\/thy.2019.0450","volume":"30","author":"Parihar","year":"2020","journal-title":"Thyroid"},{"key":"10.1016\/j.tranon.2021.101295_bib0016","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1007\/s00259-018-4036-x","article-title":"Novel use of 177Lu-DOTA-RGD2 in treatment of 68Ga-DOTA-RGD2-avid lesions in papillary thyroid cancer with TENIS","volume":"45","author":"Parihar","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.tranon.2021.101295_bib0017","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1007\/s002590100599","article-title":"End-stage renal disease after treatment with 90 Y-DOTATOC","volume":"28","author":"Cybulla","year":"2001","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.tranon.2021.101295_bib0018","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00259-002-0982-3","article-title":"Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine","volume":"30","author":"Rolleman","year":"2003","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.tranon.2021.101295_bib0019","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0360-3016(91)90171-Y","article-title":"Tolerance of normal tissue to therapeutic irradiation","volume":"21","author":"Emami","year":"1991","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.tranon.2021.101295_bib0020","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1667\/RR3105","article-title":"Renal toxicity after radionuclide therapy","volume":"161","author":"Lambert","year":"2004","journal-title":"Radiat. Res."},{"key":"10.1016\/j.tranon.2021.101295_bib0021","first-page":"19","article-title":"Radionuclide therapy for neuroendocrine tumors","author":"Cives","year":"2017","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.tranon.2021.101295_bib0022","first-page":"132","article-title":"Demonstration of focal physiologic in-vivo somatostatin receptor expression in the caput epididymis of the testes on 68Ga-DOTANOC PET\/CT and 177Lu-DOTATATE post-therapy whole body scintigraphy","volume":"8","author":"Parihar","year":"2020","journal-title":"Asia Ocean J. Nucl. Med. Biol."},{"key":"10.1016\/j.tranon.2021.101295_bib0023","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/RLU.0000000000003541","article-title":"Response to Concomitant enzalutamide and 177Lu-PSMA-617 radioligand therapy in atm-mutated metastatic castration resistant prostate cancer","volume":"46","author":"Satapathy","year":"2021","journal-title":"Clin. Nucl. Med."},{"key":"10.1016\/j.tranon.2021.101295_bib0024","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.2967\/jnumed.110.075101","article-title":"Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention","volume":"51","author":"Vegt","year":"2010","journal-title":"J. Nucl. Med."},{"issue":"46 Suppl 1","key":"10.1016\/j.tranon.2021.101295_bib0025","first-page":"199S","article-title":"The promise of targeted {alpha}-particle therapy","author":"Mulford","year":"2005","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.tranon.2021.101295_bib0026","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1007\/s00259-008-0778-1","article-title":"Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors","volume":"35","author":"Bodei","year":"2008","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.tranon.2021.101295_bib0027","first-page":"1323","article-title":"Human kidney as target for somatostatin: high affinity receptors in tubules and vasa recta","volume":"77","author":"Reubi","year":"1993","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tranon.2021.101295_bib0028","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1369\/jhc.2008.950998","article-title":"Expression of somatostatin and somatostatin receptor subtypes 1-5 in human normal and diseased kidney","volume":"56","author":"Bhandari","year":"2008","journal-title":"J. Histochem. Cytochem."},{"key":"10.1016\/j.tranon.2021.101295_bib0029","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.urology.2007.03.025","article-title":"Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms","volume":"70","author":"Baccala","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.tranon.2021.101295_bib0030","doi-asserted-by":"crossref","first-page":"e329","DOI":"10.1097\/RLU.0000000000002172","article-title":"68Ga-PSMA-HBED-CC-avid synchronous urinary bladder paraganglioma in a patient with metastatic prostate carcinoma","volume":"43","author":"Parihar","year":"2018","journal-title":"Clin. Nucl. Med."},{"key":"10.1016\/j.tranon.2021.101295_bib0031","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1097\/RLU.0000000000002764","article-title":"68Ga-PSMA-HBED-CC PET\/CT and 18F-FDG PET\/CT in Ewing sarcoma","volume":"45","author":"Parihar","year":"2020","journal-title":"Clin. Nucl. Med."},{"key":"10.1016\/j.tranon.2021.101295_bib0032","doi-asserted-by":"crossref","first-page":"e414","DOI":"10.1097\/RLU.0000000000002265","article-title":"68Ga-prostate-specific membrane antigen PET\/CT and 18F-FDG PET\/CT of primary signet ring cell breast adenocarcinoma","volume":"43","author":"Parihar","year":"2018","journal-title":"Clin. Nucl. Med."},{"key":"10.1016\/j.tranon.2021.101295_bib0033","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.2967\/jnumed.117.190215","article-title":"Detection of Synchronous primary malignancies with68Ga-labeled prostate-specific membrane antigen PET\/CT in patients with prostate cancer: frequency in 764 patients","volume":"58","author":"Osman","year":"2017","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.tranon.2021.101295_bib0034","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1002\/(SICI)1097-0142(19971215)80:12+<2591::AID-CNCR35>3.0.CO;2-5","article-title":"Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: improved canner therapy administered to a nude mouse model in relation to the internal radiation dosimetry","author":"Behr","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.tranon.2021.101295_bib0035","doi-asserted-by":"crossref","first-page":"145","DOI":"10.4103\/ijnm.IJNM_144_17","article-title":"Metabolic Bone superscan in carcinoma breast with occult graves\u2019 disease: looking beyond skeletal metastases","volume":"33","author":"Parihar","year":"2018","journal-title":"Indian J. Nucl. Med."},{"key":"10.1016\/j.tranon.2021.101295_bib0036","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s00259-011-1937-3","article-title":"The tumour sink effect on the biodistribution of 68Ga-DOTA- octreotate: implications for peptide receptor radionuclide therapy","volume":"39","author":"Beauregard","year":"2012","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.tranon.2021.101295_bib0037","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1089\/ars.2013.5668","article-title":"Ionizing radiation-induced DNA damage, response, and repair","volume":"21","author":"Santivasi","year":"2014","journal-title":"Antioxid. Redox Signal"},{"key":"10.1016\/j.tranon.2021.101295_bib0038","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2307\/3570812","article-title":"Interpretation of some results of radiotherapy and an attempt at determining a logical technique of treatment","volume":"10","author":"Bergonie","year":"1959","journal-title":"Radiat. Res."},{"key":"10.1016\/j.tranon.2021.101295_bib0039","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1001\/jama.1927.02680290001001","article-title":"Functional studies throughout the course of roentgen-ray nephritis in dogs","volume":"88","author":"Hartman","year":"1927","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.tranon.2021.101295_bib0040","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1148\/8.2.142","article-title":"The relative sensitivity of the kidney to irradiation","volume":"8","author":"Doub","year":"1927","journal-title":"Radiology"},{"key":"10.1016\/j.tranon.2021.101295_bib0041","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.celrep.2014.04.018","article-title":"In vivo clonal analysis reveals lineage-restricted progenitor characteristics in mammalian kidney development, maintenance, and regeneration","volume":"7","author":"Rinkevich","year":"2014","journal-title":"Cell Rep."},{"issue":"46 Suppl 1","key":"10.1016\/j.tranon.2021.101295_bib0042","first-page":"83S","article-title":"Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate","author":"Valkema","year":"2005","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.tranon.2021.101295_bib0043","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13014-021-01764-y","article-title":"Radiation-induced kidney toxicity: molecular and cellular pathogenesis","volume":"16","author":"Klaus","year":"2021","journal-title":"Radiat. Oncol."},{"key":"10.1016\/j.tranon.2021.101295_bib0044","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3109\/02841866409134143","article-title":"Radiation nephritis","volume":"2","author":"Luxton","year":"1964","journal-title":"Acta Radiol. Ther. Phys. Biol."},{"key":"10.1016\/j.tranon.2021.101295_bib0045","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1056\/NEJMra0904569","article-title":"The tumor lysis syndrome","volume":"364","author":"Howard","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tranon.2021.101295_bib0046","doi-asserted-by":"crossref","first-page":"752","DOI":"10.2967\/jnumed.118.217380","article-title":"Tumor lysis syndrome: a rare but serious complication of radioligand therapies","volume":"60","author":"Huang","year":"2019","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.tranon.2021.101295_bib0047","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1200\/JCO.2010.33.7873","article-title":"Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue[90Y-DOTA]-TOC in metastasized neuroendocrine cancers","volume":"29","author":"Imhof","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2021.101295_bib0048","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.tranon.2021.101295_bib0049","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1093\/ckj\/sfz101","article-title":"Renal outcomes of radioligand therapy: experience of 177lutetium\u2014Prostate-specific membrane antigen ligand therapy in metastatic castrate-resistant prostate cancer","volume":"13","author":"Gallyamov","year":"2020","journal-title":"Clin. Kidney J."},{"key":"10.1016\/j.tranon.2021.101295_bib0050","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1093\/ndt\/gfw338","article-title":"Nephrotoxicity of anticancer treatment","volume":"32","author":"Ma\u0142yszko","year":"2017","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.tranon.2021.101295_bib0051","first-page":"533","article-title":"Risk factors for acute renal failure: inherent and modifiable risks","volume":"11","author":"Leblanc","year":"2005","journal-title":"Curr. Opin. Crit. Care"},{"key":"10.1016\/j.tranon.2021.101295_bib0052","unstructured":"National Cancer Institute. Common Terminology Criteria For Adverse Events (CTCAE) Common Terminology Criteria for Adverse Events (CTCAE) v5.0 [Internet]. 2017."},{"key":"10.1016\/j.tranon.2021.101295_bib0053","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/snuc\/2002.31025","article-title":"Phase I study of peptide receptor radionuclide therapy with [111In-DTPA0]octreotide: the Rotterdam experience","volume":"32","author":"Valkema","year":"2002","journal-title":"Semin. Nucl. Med."},{"key":"10.1016\/j.tranon.2021.101295_bib0054","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s002590050476","article-title":"Yttrium-90 DOTATOC: first clinical results","volume":"26","author":"Otte","year":"1999","journal-title":"Eur. J. Nucl. Med."},{"key":"10.1016\/j.tranon.2021.101295_bib0055","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1093\/ndt\/16.5.1082","article-title":"Radiation nephropathy after radiotherapy in metastatic medullary thyroid carcinoma","volume":"16","author":"Stoffel","year":"2001","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.tranon.2021.101295_bib0056","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S0272-6386(01)80135-9","article-title":"A new cause of renal thrombotic microangiopathy: yttrium 90-DOTATOC internal radiotherapy","volume":"37","author":"Moll","year":"2001","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.tranon.2021.101295_bib0057","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1007\/s00259-004-1571-4","article-title":"Receptor radionuclide therapy with 90Y- [DOTA] 0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours","volume":"31","author":"Bodei","year":"2004","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.tranon.2021.101295_bib0058","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1479-5876-11-17","article-title":"Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study","volume":"11","author":"Marincek","year":"2013","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.tranon.2021.101295_bib0059","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1159\/000324096","article-title":"Peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATOC in advanced neuroendocrine tumors: results from a Danish cohort treated in Switzerland","volume":"93","author":"Pfeifer","year":"2011","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.tranon.2021.101295_bib0060","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1007\/s00259-016-3382-9","article-title":"Nephrotoxicity after PRRT with 177Lu-DOTA-octreotate","volume":"43","author":"Bergsma","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.tranon.2021.101295_bib0061","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","article-title":"Treatment with the radiolabeled somatostatin analog [177Lu- DOTA0,Tyr3]octreotate: toxicity, efficacy, and survival","volume":"26","author":"Kwekkeboom","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2021.101295_bib0062","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s00259-013-2559-8","article-title":"Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours","volume":"41","author":"Romer","year":"2014","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.tranon.2021.101295_bib0063","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00259-014-2893-5","article-title":"Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors","volume":"42","author":"Bodei","year":"2015","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.tranon.2021.101295_bib0064","series-title":"Oral presentation at the 2021 ASCO annual meeting","author":"Strosberg","year":"2021"},{"key":"10.1016\/j.tranon.2021.101295_bib0065","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/s00259-017-3895-x","article-title":"Third-line treatment and 177 Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review","volume":"45","author":"Eyben","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.tranon.2021.101295_bib0066","doi-asserted-by":"crossref","first-page":"97S","DOI":"10.2967\/jnumed.115.170167","article-title":"PSMA-based radioligand therapy for metastatic castration-resistant prostate cancer: the bad berka experience since 2013","volume":"57","author":"Kulkarni","year":"2016","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.tranon.2021.101295_bib0067","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2214\/AJR.18.20845","article-title":"Radioligand therapy with 177Lu-PSMA for metastatic castration-resistant prostate cancer: a systematic review and meta-analysis","volume":"213","author":"Yadav","year":"2019","journal-title":"Am. J. Roentgenol."},{"key":"10.1016\/j.tranon.2021.101295_bib0068","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00259-019-04583-2","article-title":"The 68Ga\/177Lu-theragnostic concept in PSMA-targeting of metastatic castration\u2013resistant prostate cancer: impact of post-therapeutic whole-body scintigraphy in the follow-up","volume":"47","author":"Maffey-Steffan","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.tranon.2021.101295_bib0069","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.eururo.2018.11.016","article-title":"Treatment outcome, toxicity, and predictive factors for radioligand therapy with 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer","volume":"75","author":"Heck","year":"2019","journal-title":"Eur. Urol."},{"key":"10.1016\/j.tranon.2021.101295_bib0070","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1093\/ckj\/sfz101","article-title":"Renal outcomes of radioligand therapy: experience of 177lutetium-prostate-specific membrane antigen ligand therapy in metastatic castrate-resistant prostate cancer","volume":"13","author":"Gallyamov","year":"2021","journal-title":"Clin. Kidney J."},{"key":"10.1016\/j.tranon.2021.101295_bib0071","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.tranon.2021.101295_bib0072","first-page":"1","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","author":"Sartor","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.tranon.2021.101295_bib0073","first-page":"1929","article-title":"D-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake","volume":"38","author":"Bernard","year":"1997","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.tranon.2021.101295_bib0074","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/935351","article-title":"Kidney dosimetry in (177)Lu and (90)Y peptide receptor radionuclide therapy: influence of image timing, time-activity integration method, and risk factors","volume":"2013","author":"Guerriero","year":"2013","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.tranon.2021.101295_bib0075","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3413\/nukmed-0069","article-title":"Molecular imaging of reduced renal uptake of radiolabelled [DOTA0,Tyr3]octreotate by the combination of lysine and Gelofusine in rats","volume":"47","author":"Rolleman","year":"2008","journal-title":"Nuklearmedizin"},{"key":"10.1016\/j.tranon.2021.101295_bib0076","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/S0140-6736(94)91366-8","article-title":"Reactions to gelatin plasma expanders","volume":"344","author":"Watkins","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.tranon.2021.101295_bib0077","first-page":"3825","article-title":"Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives","volume":"55","author":"Behr","year":"1995","journal-title":"Cancer Res."},{"key":"10.1016\/j.tranon.2021.101295_bib0078","doi-asserted-by":"crossref","first-page":"749","DOI":"10.2967\/jnumed.111.098665","article-title":"Reduction of renal uptake of radiolabeled octreotate by amifostine coadministration","volume":"53","author":"Melis","year":"2012","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.tranon.2021.101295_bib0079","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1021\/bc0602329","article-title":"Design, synthesis, and evaluation of [188Re]organorhenium-labeled antibody fragments with renal enzyme-cleavable linkage for low renal radioactivity levels","volume":"18","author":"Uehara","year":"2007","journal-title":"Bioconjug. Chem."},{"issue":"Suppl.2","key":"10.1016\/j.tranon.2021.101295_bib0080","first-page":"S240","article-title":"Additive effect of an angiontensin II blocker to kidney protection by lysine in a rat model of radiation nephropathy","volume":"34","author":"Rolleman","year":"2007","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.tranon.2021.101295_bib0081","first-page":"659","article-title":"Lymphatic toxicity in patients after peptide-receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE and 90Y-DOTATOC","volume":"24","author":"Sierra","year":"2009","journal-title":"Cancer Biother. Radiopharm."},{"key":"10.1016\/j.tranon.2021.101295_bib0082","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1053\/j.semnuclmed.2012.01.002","article-title":"Peptides and receptors in image-guided therapy: theranostics for neuroendocrine neoplasms","volume":"42","author":"Baum","year":"2012","journal-title":"Semin. Nucl. Med."},{"issue":"1","key":"10.1016\/j.tranon.2021.101295_bib0083","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/jmrs.227","article-title":"Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy","volume":"64","author":"Emmett","year":"2017","journal-title":"J. Med. Radiat. Sci."},{"key":"10.1016\/j.tranon.2021.101295_bib0084","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1007\/s00259-008-0778-1","article-title":"Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors","volume":"35","author":"Bodei","year":"2008","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.tranon.2021.101295_bib0085","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s002590100574","article-title":"[177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients","volume":"28","author":"Kwekkeboom","year":"2001","journal-title":"Eur. J. Nucl. Med."},{"key":"10.1016\/j.tranon.2021.101295_bib0086","first-page":"99","article-title":"3D absorbed dose calculations based on SPECT: evaluation for 111In\/90Y therapy using Monte Carlo simulations","volume":"18","author":"Ljungberg","year":"2003","journal-title":"Cancer Biother. Radiopharm."},{"issue":"4","key":"10.1016\/j.tranon.2021.101295_bib0087","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2967\/jnumed.118.219352","article-title":"Dosimetry of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes","volume":"60","author":"Violet","year":"2019","journal-title":"J. Nucl. Med."},{"issue":"17","key":"10.1016\/j.tranon.2021.101295_bib0088","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6560\/ab32a1","article-title":"Personalized kidney dosimetry in 177Lu-octreotate treatment of neuroendocrine tumours: a comparison of kidney dosimetry estimates based on a whole organ and small volume segmentations","volume":"64","author":"Hou","year":"2019","journal-title":"Phys. Med. Biol."},{"issue":"5","key":"10.1016\/j.tranon.2021.101295_bib0089","first-page":"610","article-title":"Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC","volume":"43","author":"Waldherr","year":"2002","journal-title":"J. Nucl. Med."},{"issue":"8","key":"10.1016\/j.tranon.2021.101295_bib0090","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.2967\/jnumed.111.090373","article-title":"Response and long-term control of bone metastases after peptide receptor radionuclide therapy with (177)Lu-octreotate","volume":"52","author":"Ezziddin","year":"2011","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.tranon.2021.101295_bib0091","doi-asserted-by":"crossref","unstructured":"Kalogianni E., Ruiz D.L., Corcoran B.J., Devlin L.A., Vivian G.C., Mulholland N.J. 177Lu-Dotatate therapy for the treatment of metastatic neuroendocrine tumours in a patient on haemodialysis\u2014Dosimetric considerations. BJR case reports. 2015 Aug 18:20150177.","DOI":"10.1259\/bjrcr.20150177"},{"issue":"2","key":"10.1016\/j.tranon.2021.101295_bib0092","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2967\/jnmt.115.168146","article-title":"177Lu-DOTATATE PRRT in patients with metastatic neuroendocrine tumor and a single functioning kidney: tolerability and effect on renal function","volume":"44","author":"Ranade","year":"2016","journal-title":"J. Nucl. Med. Technol."},{"issue":"11","key":"10.1016\/j.tranon.2021.101295_bib0093","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.2967\/jnumed.118.223149","article-title":"177Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer patients with a single functioning kidney","volume":"60","author":"Zhang","year":"2019","journal-title":"J. Nucl. Med."},{"issue":"10","key":"10.1016\/j.tranon.2021.101295_bib0094","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.2967\/jnumed.120.251512","article-title":"Somatostatin receptor imaging and theranostics: current practice and future prospects","volume":"62","author":"Park","year":"2021","journal-title":"J. Nucl. Med."},{"issue":"1","key":"10.1016\/j.tranon.2021.101295_bib0095","doi-asserted-by":"crossref","first-page":"92","DOI":"10.2967\/jnumed.120.245068","article-title":"Effect of tumor perfusion and receptor density on tumor control probability in 177Lu-DOTATATE therapy: an in silico analysis for standard and optimized treatment","volume":"62","author":"Jim\u00e9nez-Franco","year":"2021","journal-title":"J. Nucl. Med."}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523321002862?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523321002862?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:21:42Z","timestamp":1761844902000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523321002862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":95,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S1936523321002862"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2021.101295","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nephrotoxicity after radionuclide therapies","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2021.101295","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101295"}}